This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by Theodore Laetsch, University of Texas Southwestern Medical Center
Sponsor:
Information provided by (Responsible Party):
Theodore Laetsch, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT02557854
First received: September 21, 2015
Last updated: February 6, 2017
Last verified: February 2017
  Purpose
The purpose of this study is to determine whether Doxil (liposomal doxorubicin) given prior to MR-HIFU Hyperthermia is safe for the treatment of pediatric and young adult patients with recurrent and refractory solid tumors.

Condition Intervention Phase
Rhabdomyosarcoma Neuroblastoma Sarcoma Sarcoma, Ewing Osteosarcoma Drug: Doxorubicin HCl liposomal injection Device: Philips Sonalleve MR-HIFU Hyperthermia Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Theodore Laetsch, University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Rate of dose limiting toxicities (DLTs) during cycle 1 of therapy with MR-HIFU hyperthermia directed liposomal doxorubicin [ Time Frame: 4 weeks ]
    Dose limiting toxicities are generally CTCAE v4.03 grade 3-5 toxicities with specific exceptions detailed in the protocol.


Secondary Outcome Measures:
  • Terminal half-life (T1/2) of Doxil when delivered with MR-HIFU hyperthermia [ Time Frame: 48 hours following first dose ]
  • Volume of distribution (L/m2) of Doxil when delivered with MR-HIFU hyperthermia [ Time Frame: 48 hours following first dose ]
  • Clearance (mL/min) of Doxil when delivered with MR-HIFU hyperthermia [ Time Frame: 48 hours following first dose ]
  • Adverse events associated with Doxil when administered in combination with MR-HIFU hyperthermia [ Time Frame: 6 months ]
  • Percentage of patients with relapsed or refractory solid tumors treated with MR-HIFU hyperthermia and Doxil who demonstrate disease progression at a MR-HIFU treated lesion [ Time Frame: Through study completion, an average of 1 year ]
  • Tumor response to MR-HIFU with liposomal doxorubicin [ Time Frame: 6 months ]
  • Percentage of patients treated with MR-HIFU hyperthermia who are able to receive hyperthermia (41-45C) to greater than 75% of the predetermined treatment volume for greater than 75% of the planned treatment duration [ Time Frame: Day 1 ]

Estimated Enrollment: 14
Actual Study Start Date: December 2016
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Doxil + MR-HIFU Hyperthermia
Liposomal doxorubicin (Doxil) 50mg IV every 4 weeks followed by Magnetic Resonance High Intensity Focused Ultrasound hyperthermia (MR-HIFU) with Philips Sonalleve System to 42C for 30 minutes every 4 weeks
Drug: Doxorubicin HCl liposomal injection
50mg IV every 4 weeks
Other Name: Doxil
Device: Philips Sonalleve MR-HIFU Hyperthermia
Hyperthermia to 42C for 30 minutes every 4 weeks

  Eligibility

Ages Eligible for Study:   1 Year to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 1-40 years
  • Histologically confirmed malignant extra-cranial solid tumor
  • The subject's tumor must have relapsed after or failed to respond to frontline therapy and there must be no other known curative therapies available.
  • Subject must have a life expectancy of > 8 weeks
  • Karnofsky performance status > 50% for patients >16 years of age, or Lansky performance status > 50% for patients < 16 years of age.
  • The subject must have at least 1 measurable target lesion >10mm in longest dimension that is in an anatomic location treatable by MR-HIFU. Note that for this study, lesions in bone WILL be considered measurable provided they meet the other criteria by RECIST and are confirmed to be metabolically active on baseline studies by either MIBG uptake (for neuroblastomas) or PET avidity. Target lesions should be located so that they can be adequately heated by a hyperthermia treatment cell with a diameter of up to 58 mm, centered at a depth of 35 to 80 mm from the skin. There should be no staples, implants, extensive scarring, or other highly ultrasound absorbing or reflecting tissue in the expected beam path. For the first 5 patients enrolled on this study only, the lesion must be located in the extremities or pelvis to be considered treatable by MR-HIFU.
  • The subject must have recovered from the acute toxic effects of all prior therapy with the exception of alopecia. The following time must have elapsed from the last dose of the following medications to study enrollment:

    • myelosuppressive chemotherapy 14 days
    • hematopoetic growth factors 7 days (14 days for Neulasta)
    • biologic agent 7 days
    • monoclonal antibody 3 half-lives
    • immunotherapy (ie tumor vaccines) 42 days
    • palliative small port XRT 14 days
    • substantial bone marrow XRT 6 weeks
    • stem cell transplant or infusion without TBI 12 weeks
    • total body irradiation (TBI) 24 weeks
  • Adequate organ and marrow function as defined below:

    • absolute neutrophil count ≥ 1,000/mcL
    • platelets ≥ 75,000/mcl (without transfusion for 7 days)
    • hemoglobin > 8g/dL (may receive transfusions)
    • total bilirubin < 1.5 mg/dL
    • ALT(SPGT) < 225 U/L (45 U/L defined as ULN)
    • creatinine clearance or radioisotope GFR > 70 mL/min/1.73m2 OR a serum creatinine (mg/dL) less than or equal to the following:
    • Age (yrs)-----Male (mg/dL)-----Female (mg/dL)
    • 1-1.99----------0.6------------------0.6
    • 2-5.99----------0.8------------------0.8
    • 6-9.99----------1--------------------1
    • 10-12.99------1.2------------------1.2
    • 13-15.99------1.5------------------1.4
    • >16-------------1.7------------------1.4
  • Adequate cardiac function defined as an ejection fraction > 50% or shortening fraction > 27%
  • Cumulative lifetime anthracycline dose of < 450mg/m2
  • Females and males of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A male of child-bearing potential is any male (regardless of sexual orientation, having undergone a vasectomy, or remaining celibate by choice) who has attained Tanner stage III or greater sexual development. A female of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has undergone menarche OR is > 13 years of age
  • Females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment.
  • Signed written informed consent must be obtained prior to any study procedures.

Exclusion Criteria:

  • Subjects may not be receiving any other investigational agents or anticancer therapies.
  • Subjects with known active brain metastases will be excluded from this clinical trial. Patients with brain metastases that have been treated and stable for > 30 days following treatment will be eligible.
  • Subjects who have received prior Doxil and progressed on this therapy are not eligible, but subjects may have received prior doxorubicin.
  • Subjects with a history of tumor progression within 30 days of anthracycline administration are not eligible. However, subjects who have previously received an anthracycline and subsequently relapse greater than 30 days after their most recent prior dose of anthracycline will be eligible.
  • History of allergic reactions attributed to doxorubicin or Doxil
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
  • Subjects with a contraindication to MR-HIFU
  • Subjects with conditions that carry high anesthetic risk in the opinion of the treating anesthesiologist are not eligible (i.e. subjects with significant airway compression by tumor or craniofacial abnormalities)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02557854

Locations
United States, Texas
UT Southwestern Medical Center/Children's Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Theodore W Laetsch, MD    214-456-6405    ted.laetsch@utsouthwestern.edu   
Principal Investigator: Theodore Laetsch, MD         
Sponsors and Collaborators
Theodore Laetsch
  More Information

Responsible Party: Theodore Laetsch, Assistant Professor of Pediatrics, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT02557854     History of Changes
Other Study ID Numbers: UTSW-HIFU-001
Study First Received: September 21, 2015
Last Updated: February 6, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Sarcoma
Neuroblastoma
Osteosarcoma
Rhabdomyosarcoma
Sarcoma, Ewing
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Myosarcoma
Neoplasms, Muscle Tissue
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 17, 2017